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ess: bob.hancox@dmhdSummary Introduction: Regular use of beta-agonists leads to tolerance to their
bronchodilator effects. This is easily demonstrated if dilation is tested following
methacholine challenge. It is not known how quickly tolerance develops or how long
it lasts after stopping beta-agonist therapy.
Methods: Ten subjects with stable asthma were studied. Following 2 weeks
without beta-agonists, methacholine was inhaled to induce a 20% reduction in FEV1.
The response to inhaled salbutamol (100, 100, 200 mg at 5-min intervals) was then
measured. This procedure was repeated 24 h after one dose and 24 h after 3, 7 and
14 days of inhaled formoterol 12 mg twice daily, and 3 and 5 days after formoterol
was discontinued. Unscheduled use of beta-agonists was not permitted.
Results: Bronchodilator tolerance, assessed by a reduction of the area under the
salbutamol dose–response curve, occurred after 1 dose of formoterol (28%
reduction, 95% CI 12, 45%), increased up to 1 week and plateaued between 1 and
2 weeks (58% reduction, 95% CI 38, 78%). Three days after stopping formoterol, the
response to salbutamol was similar to baseline (12% reduction, 95% CI 9, 33%). The
first dose of formoterol provided significant bronchoprotection to methacholine (1.6
doubling doses, P ¼ 0:007). This diminished with regular treatment and by 2 weeks
the PD20 methacholine was not significantly different to baseline.
Conclusions: Bronchodilator tolerance occurs after a single dose and reaches a
maximum after 1 week of regular formoterol. Sensitivity recovers 3 days after
stopping treatment.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
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Long-acting beta-agonists are recommended for
patients with persistent asthma symptoms despite
inhaled corticosteroids.1 They improve symptoms
and lung function and reduce the number of
exacerbations and the need for additionaled.
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found to reduce hospital admissions3 and there
have been indications that they may increase
asthma mortality or serious exacerbations, espe-
cially in patients not taking inhaled corticoster-
oids.4,5 One mechanism by which long-acting beta-
agonists could lead to an adverse event is the
development of tolerance to beta-agonists.
Tolerance is known to occur to the extrapulmon-
ary effects of beta-agonists6 and also to their
bronchoprotective effects7,8 (the ability to prevent
bronchoconstriction). Demonstrating tolerance to
bronchodilation has been more difficult. Studies in
stable asthmatics have had inconsistent results.9,10
However, studies that have assessed bronchodila-
tion after prior bronchoconstriction with metha-
choline have consistently shown marked tolerance
to bronchodilation.11–14 A recent meta-analysis also
concluded that regular beta-agonist treatment
decreased the bronchodilator response to subse-
quent beta-agonists.15
While bronchoprotection tolerance can be shown
after a single day of treatment with long-acting
beta-agonist,8 the time course of the development
of tolerance to bronchodilation is unknown.15 This
study was designed to assess the speed of onset of
bronchodilator tolerance using the long-acting
beta-agonist formoterol.Methods
Subjects were asthmatics who were not using long-
acting beta-agonists. Pregnant and lactating wo-
men were excluded, as were those who had used
oral corticosteroids in the previous 3 months or had
changed asthma treatment in the previous 6 weeks.
Subjects with a PD20 methacholine41.5mg on day
0 were withdrawn.
There was an initial 2-week washout period
during which no beta-agonist was used. Following
this, subjects underwent a methacholine challenge
and salbutamol response (day 0). Subjects then
inhaled formoterol 12 mg twice daily (Foradil aero-
liser) for the next 2 weeks, except where this was
omitted for 24 h before each challenge. Methacho-
line challenges and salbutamol responses were
repeated on day 1 (24 h after a single dose of
formoterol) and on days 3, 7, and 14 of formoterol
treatment (after 4, 11 and 24 doses of formoterol,
respectively). Challenges were also performed 3
and 5 days after stopping treatment.
Methacholine challenge was performed using a
modified Yan protocol.16 Baseline FEV1 was the
highest of three consistent measurements. Subjectsthen inhaled doubling doses of nebulised metha-
choline from 0.0073 to 3.75mg (0.04–19 mmol) via 1
or 2 breaths from a dosimeter to a maximum
cumulative dose of 7.5mg. The FEV1 was measured
1min after each dose. Once FEV1 had fallen by
X20% from baseline, methacholine challenge was
stopped. The PD20 (cumulative dose) was calcu-
lated by linear interpolation. Where the FEV1 fell
o20% from baseline (1 subject on 2 occasions), an
arbitrary value of 15mg was taken as the PD20.
Salbutamol 100, 100 and 200 mg via metered dose
inhaler and Volumatic spacer was given at 0, 5 and
10min after challenge, respectively. FEV1 was
measured 5min after each dose of salbutamol.
Total measured response time was therefore
15min.
The main outcome measure was the area under
the curve (AUC) for the change in FEV1 after
inhaled salbutamol. The change in FEV1 was
expressed as a percentage of the fall in FEV1
induced by methacholine. Changes from baseline
were assessed by paired Student’s t-tests. Previous
studies indicate that the baseline FEV1, dose of
methacholine used and the fall in FEV1 may be
significant covariates of the AUC.12 A further
analysis examined the changes in the AUC using
these as covariates (repeated measures ANCOVA).
Data from previous studies indicated that a sample
size of 12 subjects would give 80% power to detect
a 30% fall in AUC at a ¼ 0:05:12
A secondary outcome measure was the final
(15min) FEV1 following salbutamol treatment.
Bronchoprotection was assessed by measuring
changes in the log PD20 methacholine.Results
Fourteen subjects were recruited of whom three
were withdrawn on day 0 because their PD20 was
41.5mg (7.7 mmol). One further subject withdrew
after day 3 because of an upper respiratory tract
infection. Data are therefore available for 10
subjects, 6 female, aged 20–61 years. Five subjects
were taking inhaled corticosteroids. One subject
did not attend the challenge on day 1. AUC data 3
days after formoterol was stopped are unavailable
for technical reasons in another subject.
The mean baseline FEV1 on day 1, 24 h after the
first dose of formoterol, increased by 140ml
(P ¼ 0:006). This remained relatively constant
during formoterol treatment, although after 2
weeks the difference from baseline was no longer
statistically significant. Three and 5 days after
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day 0 (Table 1).
The geometric mean PD20 methacholine in-
creased after the first dose of formoterol by 1.6
doubling doses (P ¼ 0:007). The bronchoprotection
afforded by the formoterol decreased thereafter.
After 2 weeks of treatment, the PD20 was not
significantly different to day 0 (Table 1).
The AUC for salbutamol response fell during
formoterol treatment (Table 1, Fig. 1). After one
dose the AUC had fallen by 28% (95% confidence
interval 12, 45%). It continued to decrease up to 1
week (61% (95% CI: 27, 95) lower), and plateaued
between 1 and 2 weeks (58% (95% CI: 38, 78)
lower). The AUC recovered 3 days after stopping
formoterol (12% lower than baseline (95% CI: 9,
33%)).
The change in AUC from baseline was statistically
significant for all measurements during formoterol
therapy without taking covariates into account
(Table 1). In the covariate analysis, the reduction
in AUC after the first dose of formoterol was not
statistically significant after adjusting for the
baseline FEV1, the PD20 and the fall in FEV1 induced
by methacholine. After 1 and 2 weeks the decrease
in AUC from day 0 was significant, even after
adjusting for these covariates (P ¼ 0:002 at 2
weeks) (Table 1).
The final FEV1 after 400 mg of salbutamol (15min
after the end of the methacholine challenge)
showed the same pattern as the AUC, with a
substantial reduction at 1 and 2 weeks. The mean
post-salbutamol FEV1 was 3.01 L on day 0 and 2.60 L
on day 14 (n ¼ 10) (95% confidence interval for
difference 0.20–0.61 L, P ¼ 0:006 on covariate
analysis) (Table 1, Fig. 2).Discussion
This study indicates that bronchodilator tolerance
develops rapidly, with a reduced response to
salbutamol after a single dose of formoterol.
Tolerance appeared to reach a plateau after 1
week of regular therapy. Beta-agonist responsive-
ness recovered quickly with little tolerance 3 days
after stopping therapy.
The pre-methacholine FEV1 was higher than
baseline throughout formoterol treatment, in
keeping with the known bronchodilator effects of
formoterol. The first dose of formoterol provided
significant bronchoprotection against methacho-
line. This degree of bronchoprotection decreased
thereafter as tolerance to bronchoprotection
occurred.Initially, the reduced response to salbutamol may
have been confounded by the bronchoprotective
effect of formoterol. This meant that more
methacholine was required to produce broncho-
constriction and the higher dose may have reduced
the response to salbutamol. Hence the covariate
analysis, which adjusts for the PD20, does not show
a statistically significant difference in the response
to salbutamol after the first dose of formoterol.
However, as the study continued and tolerance to
bronchoprotection developed, the PD20 approached
baseline values but the response to salbutamol
continued to decrease. This indicates that a true
reduction in the salbutamol response was taking
place.
This was an open-label study without a placebo
control. Bronchodilator tolerance has been shown
to occur using the methacholine model in several
double-blind randomised placebo controlled
trials.11–14 This study was designed to examine
the rate of onset of tolerance by comparing the
change in response with baseline (day 0). We had
no a priori hypothesis about the onset of tolerance
and think it is very unlikely that the lack of a
placebo control has biased our findings.
Tolerance to bronchodilation appears to follow a
similar time course to tolerance to bronchoprotec-
tion. This has been shown to occur after a single
dose17 and increase over the first 5 days of long-
acting beta-agonist therapy.8 Beta-receptor density
and activity on human lymphocytes also show a
similar pattern, with a decrease over 1 week of
beta-agonist treatment, a plateau between 1 and 2
weeks and recovery 1 week after stopping ther-
apy.18 Different mechanisms may be responsible for
early and later tolerance. It is possible that in
parallel with the rapid onset of tolerance (within
24 h), there may also be a rapid recovery from
tolerance, at least some of which will occur in the
first 24 h. Cellular studies show that receptor
downregulation involves many mechanisms includ-
ing initial uncoupling of the receptor from its
intracellular effector systems, receptor internali-
sation and reduction in receptor synthesis. The
timing of these events in human airway cells is
uncertain.19
It is possible that some of the reduction in
salbutamol response in this study was due to
residual occupancy of the beta-receptors by for-
moterol leaving fewer receptors available to bind
to salbutamol. The responses were measured 24 h
after the last dose of formoterol. At this point there
is still a small bronchodilator effect and therefore
presumably receptor occupancy.20 This may partly
account for the greater tolerance found in this
study than found by Jones et al.11 who measured
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Table 1 Baseline FEV1, geometric mean PD20 and salbutamol dose–response AUC on each of the study days.
Day 0 1 3 7 14 3 days post 5 days post
FEV1 (L) (SD)
* 2.80 (1.19)* 2.94 (1.18)* 2.92 (1.20)* 2.89 (1.21)* 2.86 (1.20)* 2.76 (1.19)* 2.73 (1.12)*
Change from day 0 (95%
confidence interval)
0.14*
(0.05, 0.22)
0.12
(0.05, 0.19)
0.10
(0.01, 0.19)
0.07
(0.04, 0.18)
0.05
(0.14, 0.04)
0.06
(0.16, 0.04)
P for change 0.006* 0.005 0.04 0.17 0.25 0.19
PD20 methacholine (mg)
**
(95% CI for mean)
0.11**
(0.03, 0.46)
0.37** (0.07,
2.14)
0.31**
(0.05, 1.84)
0.24**
(0.04, 1.38)
0.17**
(0.05, 0.60)
0.18** (0.04,
0.81)
0.16** (0.03,
0.85)
Change from day 0 (doubling doses)
(95% confidence interval)
1.57* (0.55,
2.58)
1.49*
(0.53, 2.45)
0.93
(0.09, 1.78)
0.44
(0.11, 1.00)
0.33 (0.57,
1.23)
0.29
(0.38, 0.95)
P for change 0.007* 0.007* 0.03 0.11 0.43 0.35
Final FEV1 (L)(SD)
** 3.10 (1.18)** 3.00 (1.19)** 2.85 (1.24)** 2.56 (1.15)** 2.61 (1.11)** 2.84 (1.12)** 2.88 (1.15)**
Change from day 0 (95% confidence
interval)
0.07*
(0.18, 0.04)
0.20
(0.36,0.04)
0.42
(0.69,0.16)
0.40
(0.61,0.20)
0.24*
(0.40,0.08)
0.16
(0.28,0.05)
P for change (no covariates) 0.18* 0.02 0.006 0.002 0.008* 0.01
P for change (covariate analysis) 0.18* 0.22 0.03 0.006 0.12* 0.23
AUC (%.time) (SD)** 244 (152)** 166 (151)** 126 (48)** 77 (62)** 92 (112)** 211 (169)** 219 (150)**
% change from day 0 (95%
confidence interval)
28* (45,
12)
46 (85, 7) 61 (95, 27) 58 (78,38) 12* (33, 9) 11 (24, 2)
P for change (no covariates) 0.004* 0.03 0.003 o0.001 0.22* 0.10
P for change (covariate analysis) 0.38* 0.16 0.02 0.002 0.07* 0.23
AUC results are expressed as percent recovery of the methacholine-induced fall in FEV1 time. Only subjects with complete data for all study days are included in mean values and
standard deviations. All available data are used for calculation of delta values, confidence intervals for change and P values for change. N ¼ 10; except n ¼ 9; **n ¼ 8:
R
ap
id
onset
of
toleran
ce
to
b
eta-agonist
b
ronchod
ilation
569
ARTICLE IN PRESS
0
50
100
150
200
250
300
350
baseline 1 day
formoterol
3 days
formoterol
1 week
formoterol
2 weeks
formoterol
3 days post
therapy
5 days post
therapy
A
UC
 a
s 
%
 fa
ll 
in
 F
EV
1
Figure 1 Area under the salbutamol dose–response curve
on each study day. AUC results are expressed as percent
recovery of the methacholine-induced fall in
FEV1 time. Error bars represent the standard error of
the mean. Only subjects with data for all challenges are
included (n ¼ 8).
Response to salbutamol
2
2.2
2.4
2.6
2.8
3
3.2
Baseline post
methacholine
100mcg
salbutamol
200mcg
salbutamol
400mcg
salbutamol
FE
V1
 (li
tre
s)
Baseline
day 7
day 14
Figure 2 The mean response to salbutamol after
methacholine challenge on days 0, 7 and 14. Subjects
with data for all of these challenges are included
(n ¼ 10).
S. Haney, R.J. Hancox570the salbutamol response 36 h after 2 weeks of
formoterol 12 mg twice daily (29% reduction in
AUC). Although it may have been preferable to
measure responses 36 h after the last dose of
formoterol, we considered this to be too long an
interruption in a study designed to look at the onset
of tolerance during ‘continuous treatment’.
Genetic polymorphisms in the beta2-receptor
have been shown to influence receptor down-
regulation in vitro21 and in theory these may affect
susceptibility to beta-agonist tolerance. The clin-
ical data on this are conflicting,22,23 and a recent
study found no difference in bronchodilator toler-
ance between subjects homozygous for either the
Arg-16 or Gly-16 polymorphisms.24 No studies havebeen performed looking at other polymorphisms.
Although we observed a large variation in the
degree of tolerance experienced by individuals in
this study, every subject experienced some decline
in salbutamol response. The minimum decrease in
AUC was 36% at 2 weeks and the maximum decrease
was a complete lack of salbutamol bronchodilation
(100% decrease in AUC), which occurred in two
subjects.
Testing bronchodilation after bronchoconstric-
tion may be seen as analogous to drug use by
patients, where short acting beta-agonists are
taken to relieve symptoms. It is of concern that
the results show a mean loss of salbutamol
bronchodilation of over 50% after 1 week of
treatment. By this time much of the bronchopro-
tective effect of the long-acting beta-agonist had
also been lost. Some subjects had very little
response to 400 mg of salbutamol. Wraight et al.14
showed that tolerance increases with increasing
degrees of bronchoconstriction. These patients
could be at risk during an acute exacerbation of
asthma if bronchoconstriction does not respond to
conventional short-acting beta-agonist therapy.
Given that a reduced response to salbutamol is
evident after the first dose of formoterol, it seems
impossible to avoid it by altering the dosing
strategy. Patients taking long-acting beta-agonists
need to be aware that their reliever inhaler may be
less effective.Acknowledgments
The authors would like to thank the study partici-
pants, Dr. J. McLachlan and the staff of the Waikato
Hospital Respiratory Laboratory and Research Unit.
The study was funded by the Respiratory Research
Fund, Waikato Hospital.References
1. British guideline on the management of asthma. Thorax
2003;58(Suppl. 1):1–83.
2. Pauwels RA, Lofdahl C-G, Postma DS, et al. Effect of inhaled
formoterol and budesonide on exacerbations of asthma. N
Engl J Med 1997;337:1405–11.
3. Lanes SL, Lanza LL, Wentworth CE. Risk of emergency care,
hospitalization, and ICU stays for acute asthma among
recipients of salmeterol. Am J Respir Crit Care Med
1998;158:857–61.
4. Rickard KA. 2003 Safety alert—Serevent (salmeterol xinafo-
ate). www.fda.gov/medwatch/SAFETY/2003/serevent.htm,
Accessed 23/05/03.
5. Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R,
Meyer RJ. Serious asthma exacerbations in asthmatics
treated with high-dose formoterol. Chest 2003;124:70–4.
ARTICLE IN PRESS
Rapid onset of tolerance to beta-agonist bronchodilation 5716. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to
systemic but not to airway responses during prolonged
therapy with high dose inhaled salbutamol in asthmatics. Am
Rev Respir Dis 1989;140:586–92.
7. Cheung DM, Timmers MC, Zwinderman AH, Bel EH, Dijkman
JH, Sterk PJ. Long-term effects of a long-acting b2-
adrenoceptor agonist, salmeterol, on airway responsiveness
in patients with mild asthma. N Engl J Med
1992;327:1198–203.
8. Bhagat R, Kalra S, Swystun VA, Cockcroft DW. Rapid onset of
tolerance to the bronchoprotective effect of salmeterol.
Chest 1995;108:1235–9.
9. Aziz I, Hall IP, McFarlane LC, Lipworth BJ. b2-adrenoceptor
regulation and bronchodilator sensitivity after regular
treatment with formoterol in subjects with stable asthma.
J Allergy Clin Immunol 1998;101:337–41.
10. Lipworth BJ, Aziz I. Bronchodilator response to albuterol
after regular formoterol and effects of acute corticosteroid
administration. Chest 2000;117:156–62.
11. Jones SL, Cowan JO, Flannery EM, Hancox RJ, Herbison GP,
Taylor DR. Reversing acute bronchoconstriction in asthma:
the effect of bronchodilator tolerance after treatment with
formoterol. Eur Respir J 2001;17:368–73.
12. Hancox RJ, Aldridge RE, Cowan JO, et al. Tolerance to beta-
agonists during acute bronchoconstriction. Eur Respir J
1999;14:283–7.
13. Van der Woude HJ, Winter TH, Aalbers R. Decreased
bronchodilating effect of salbutamol in relieving methacho-
line induced moderate to severe bronchoconstriction during
high dose treatment with long acting b2 agonists. Thorax
2001;56:529–35.
14. Wraight JM, Hancox RJ, Herbison GP, Cowan JO, Flannery
EM, Taylor DR. Bronchodilator tolerance: the impact of
increasing bronchoconstriction. Eur Respir J 2003;21:810–5.15. Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis:
respiratory tolerance to regular b2-agonist use in patients
with asthma. Ann Intern Med 2004;140:802–13.
16. Yan K, Salome C, Woolcock AJ. Rapid method for measure-
ment of bronchial responsiveness. Thorax 1983;38:760–5.
17. Drotar DE, Davis EE, Cockcroft DW. Tolerance to the
bronchoprotective effect of salmeterol 12 h after starting
twice daily treatment. Ann Allergy Asthma Immunol
1998;80:31–4.
18. Van den Berg W, Leferink JG, Fokkens JK, Kreukniet J, Maes
RAA, Bruynzeel PLB. Clinical implications of drug-induced
desensitization of the beta-receptor after continuous oral
use of terbutaline. J Allergy Clin Immunol 1982;69:410–7.
19. Barnes PJ. Beta-adrenergic receptors and their regulation.
Am J Respir Crit Care Med 1995;152:838–60.
20. Rabe KF, Jorres R, Nowak D, Behr N, Magnussen H.
Comparison of the effects of salmeterol and formoterol on
airway tone and responsiveness over 24 h in bronchial
asthma. Am Rev Respir Dis 1993;147:1436–41.
21. Liggett SB. b2-adrenergic receptor pharmacogenetics. Am J
Respir Crit Care Med 2000;S197–S201.
22. Tan S, Hall IP, Dewar J, Dow E, Lipworth B. Association
between b2-adrenoceptor polymorphism and susceptibility
to bronchodilator desensitisation in moderately severe
stable asthmatics. Lancet 1997;350:995–9.
23. Israel E, Drazen JM, Liggett SB, et al. The effect of
polymorphisms of the b2-adrenergic receptor on the
response to regular use of albuterol in asthma. Am J Respir
Crit Care Med 2000;162:75–80.
24. Lee DKC, Jackson CM, Bates CE, Lipworth BJ. Cross
tolerance to salbutamol occurs independently of b2 adreno-
ceptor genotype-16 in asthmatic patients receiving regular
formoterol or salmeterol. Thorax 2004;59:662–7.
